Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study
Background This study aimed to investigate the prognostic value of the Gustave Roussy Immune score (GRIm-score) in platinum-refractory metastatic urothelial carcinoma (UC) treated with pembrolizumab. Methods This multicenter retrospective study (YUSHIMA study) evaluated 331 patients with metastatic...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical oncology 2024-09, Vol.29 (9), p.1302-1310 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1310 |
|---|---|
| container_issue | 9 |
| container_start_page | 1302 |
| container_title | International journal of clinical oncology |
| container_volume | 29 |
| creator | Tanabe, Kenji Kobayashi, Shuichiro Maezawa, Yuya Ishihara, Kensaku Inoue, Naoki Izumi, Keita Fujiwara, Motohiro Toide, Masahiro Yamamoto, Takanobu Uehara, Sho Araki, Saori Inoue, Masaharu Takazawa, Ryoji Numao, Noboru Ohtsuka, Yukihiro Tanaka, Hajime Yoshida, Soichiro Fujii, Yasuhisa |
| description | Background
This study aimed to investigate the prognostic value of the Gustave Roussy Immune score (GRIm-score) in platinum-refractory metastatic urothelial carcinoma (UC) treated with pembrolizumab.
Methods
This multicenter retrospective study (YUSHIMA study) evaluated 331 patients with metastatic UC treated with pembrolizumab after platinum-based chemotherapy between January 2018 and June 2023 at 13 institutions. We collected pretreatment variables, including the GRIm-score based on serum albumin, lactate dehydrogenase, and neutrophil-to-lymphocyte ratio. The patients were divided into low and high GRIm-score groups. Prognostic factors for overall survival (OS) and progression-free survival (PFS) were determined using the multivariate Cox proportional hazard model.
Results
During the median follow-up period of 7.3 months, 278 (84%) patients showed disease progression, and 223 (67%) died from any cause. Multivariate analysis revealed that the high GRIm-score group was an independent and significant adverse prognostic factor of both OS and PFS (hazard ratio, 1.65 and 1.82, respectively; both
p
|
| doi_str_mv | 10.1007/s10147-024-02563-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3064581561</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3097258115</sourcerecordid><originalsourceid>FETCH-LOGICAL-c256t-1a1ff792cd9d0ebbf7171de0f8a5a698898ac26f7a500fa0ccf93233a095b39d3</originalsourceid><addsrcrecordid>eNp9kctu1TAQhiNERS_wAiyQJTZsQu04iRN2VdXLkYqQgC5YRRNn3Lok9sEXqtPn4UGZcg4gsWBh2Za_-cfz_0XxUvC3gnN1HAUXtSp5VdNqWlmqJ8WBqKUqlVLVUzrLWpR9WzX7xWGMd5wL1TbVs2Jfdp2UQsiD4sdFjgm-I_voc4wbtlqW7JBF7QMyiAzYOvgb52Oymo3WLxC-YmDWsTUkiy5Fdm_TLVvPdHV5KQOaADr5sGELJiDxx8ocfLrF2cLMNARtHQmxFBASTjsBXMbgZ_uQFxjfsS_Xny5X709YTHnaPC_2DMwRX-z2o-L6_Ozz6WV59eFidXpyVWoaP5UChDGqr_TUTxzH0SihxITcdNBA23dd34GuWqOg4dwA19r0spISeN-Msp_kUfFmq0szf8sY07DYqHGewSHZM0je1k0nmlYQ-vof9M7n4Oh3RPWqIkw0RFVbSgcfI1kzrIMlCzeD4MNjhsM2w4EyHH5lOCgqerWTzuOC05-S36ERILdApCd3g-Fv7__I_gQSGqs4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3097258115</pqid></control><display><type>article</type><title>Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study</title><source>MEDLINE</source><source>SpringerLink (Online service)</source><creator>Tanabe, Kenji ; Kobayashi, Shuichiro ; Maezawa, Yuya ; Ishihara, Kensaku ; Inoue, Naoki ; Izumi, Keita ; Fujiwara, Motohiro ; Toide, Masahiro ; Yamamoto, Takanobu ; Uehara, Sho ; Araki, Saori ; Inoue, Masaharu ; Takazawa, Ryoji ; Numao, Noboru ; Ohtsuka, Yukihiro ; Tanaka, Hajime ; Yoshida, Soichiro ; Fujii, Yasuhisa</creator><creatorcontrib>Tanabe, Kenji ; Kobayashi, Shuichiro ; Maezawa, Yuya ; Ishihara, Kensaku ; Inoue, Naoki ; Izumi, Keita ; Fujiwara, Motohiro ; Toide, Masahiro ; Yamamoto, Takanobu ; Uehara, Sho ; Araki, Saori ; Inoue, Masaharu ; Takazawa, Ryoji ; Numao, Noboru ; Ohtsuka, Yukihiro ; Tanaka, Hajime ; Yoshida, Soichiro ; Fujii, Yasuhisa</creatorcontrib><description>Background
This study aimed to investigate the prognostic value of the Gustave Roussy Immune score (GRIm-score) in platinum-refractory metastatic urothelial carcinoma (UC) treated with pembrolizumab.
Methods
This multicenter retrospective study (YUSHIMA study) evaluated 331 patients with metastatic UC treated with pembrolizumab after platinum-based chemotherapy between January 2018 and June 2023 at 13 institutions. We collected pretreatment variables, including the GRIm-score based on serum albumin, lactate dehydrogenase, and neutrophil-to-lymphocyte ratio. The patients were divided into low and high GRIm-score groups. Prognostic factors for overall survival (OS) and progression-free survival (PFS) were determined using the multivariate Cox proportional hazard model.
Results
During the median follow-up period of 7.3 months, 278 (84%) patients showed disease progression, and 223 (67%) died from any cause. Multivariate analysis revealed that the high GRIm-score group was an independent and significant adverse prognostic factor of both OS and PFS (hazard ratio, 1.65 and 1.82, respectively; both
p
< 0.001) along with Eastern Cooperative Oncology Group Performance Status of ≥ 2 (both
p
< 0.001), presence of visceral metastasis (both
p
< 0.001), and hemoglobin of < 9.2 g/dL (
p
= 0.030 and
p
= 0.038). C-reactive protein of > 42 mg/L was a significant prognostic factor for OS (
p
= 0.001).
Conclusion
The GRIm-score is an independent prognostic marker for survival outcomes in patients with platinum-refractory metastatic UC treated with pembrolizumab.</description><identifier>ISSN: 1341-9625</identifier><identifier>ISSN: 1437-7772</identifier><identifier>EISSN: 1437-7772</identifier><identifier>DOI: 10.1007/s10147-024-02563-7</identifier><identifier>PMID: 38833113</identifier><language>eng</language><publisher>Singapore: Springer Nature Singapore</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antineoplastic Agents, Immunological - therapeutic use ; Biomarkers, Tumor ; C-reactive protein ; Cancer Research ; Carcinoma, Transitional Cell - drug therapy ; Carcinoma, Transitional Cell - mortality ; Carcinoma, Transitional Cell - secondary ; Chemotherapy ; Drug Resistance, Neoplasm ; Female ; Hemoglobin ; Humans ; Immunotherapy ; L-Lactate dehydrogenase ; Leukocytes (neutrophilic) ; Lymphocytes ; Male ; Medical prognosis ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Middle Aged ; Monoclonal antibodies ; Multivariate analysis ; Neutrophils ; Oncology ; Original Article ; Pembrolizumab ; Platinum ; Prognosis ; Progression-Free Survival ; Retrospective Studies ; Surgical Oncology ; Targeted cancer therapy ; Urinary Bladder Neoplasms - drug therapy ; Urinary Bladder Neoplasms - mortality ; Urinary Bladder Neoplasms - pathology ; Urologic Neoplasms - drug therapy ; Urologic Neoplasms - immunology ; Urologic Neoplasms - mortality ; Urologic Neoplasms - pathology ; Urological cancer ; Urothelial carcinoma</subject><ispartof>International journal of clinical oncology, 2024-09, Vol.29 (9), p.1302-1310</ispartof><rights>The Author(s) under exclusive licence to Japan Society of Clinical Oncology 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c256t-1a1ff792cd9d0ebbf7171de0f8a5a698898ac26f7a500fa0ccf93233a095b39d3</cites><orcidid>0009-0000-7290-1826</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10147-024-02563-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10147-024-02563-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38833113$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tanabe, Kenji</creatorcontrib><creatorcontrib>Kobayashi, Shuichiro</creatorcontrib><creatorcontrib>Maezawa, Yuya</creatorcontrib><creatorcontrib>Ishihara, Kensaku</creatorcontrib><creatorcontrib>Inoue, Naoki</creatorcontrib><creatorcontrib>Izumi, Keita</creatorcontrib><creatorcontrib>Fujiwara, Motohiro</creatorcontrib><creatorcontrib>Toide, Masahiro</creatorcontrib><creatorcontrib>Yamamoto, Takanobu</creatorcontrib><creatorcontrib>Uehara, Sho</creatorcontrib><creatorcontrib>Araki, Saori</creatorcontrib><creatorcontrib>Inoue, Masaharu</creatorcontrib><creatorcontrib>Takazawa, Ryoji</creatorcontrib><creatorcontrib>Numao, Noboru</creatorcontrib><creatorcontrib>Ohtsuka, Yukihiro</creatorcontrib><creatorcontrib>Tanaka, Hajime</creatorcontrib><creatorcontrib>Yoshida, Soichiro</creatorcontrib><creatorcontrib>Fujii, Yasuhisa</creatorcontrib><title>Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study</title><title>International journal of clinical oncology</title><addtitle>Int J Clin Oncol</addtitle><addtitle>Int J Clin Oncol</addtitle><description>Background
This study aimed to investigate the prognostic value of the Gustave Roussy Immune score (GRIm-score) in platinum-refractory metastatic urothelial carcinoma (UC) treated with pembrolizumab.
Methods
This multicenter retrospective study (YUSHIMA study) evaluated 331 patients with metastatic UC treated with pembrolizumab after platinum-based chemotherapy between January 2018 and June 2023 at 13 institutions. We collected pretreatment variables, including the GRIm-score based on serum albumin, lactate dehydrogenase, and neutrophil-to-lymphocyte ratio. The patients were divided into low and high GRIm-score groups. Prognostic factors for overall survival (OS) and progression-free survival (PFS) were determined using the multivariate Cox proportional hazard model.
Results
During the median follow-up period of 7.3 months, 278 (84%) patients showed disease progression, and 223 (67%) died from any cause. Multivariate analysis revealed that the high GRIm-score group was an independent and significant adverse prognostic factor of both OS and PFS (hazard ratio, 1.65 and 1.82, respectively; both
p
< 0.001) along with Eastern Cooperative Oncology Group Performance Status of ≥ 2 (both
p
< 0.001), presence of visceral metastasis (both
p
< 0.001), and hemoglobin of < 9.2 g/dL (
p
= 0.030 and
p
= 0.038). C-reactive protein of > 42 mg/L was a significant prognostic factor for OS (
p
= 0.001).
Conclusion
The GRIm-score is an independent prognostic marker for survival outcomes in patients with platinum-refractory metastatic UC treated with pembrolizumab.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antineoplastic Agents, Immunological - therapeutic use</subject><subject>Biomarkers, Tumor</subject><subject>C-reactive protein</subject><subject>Cancer Research</subject><subject>Carcinoma, Transitional Cell - drug therapy</subject><subject>Carcinoma, Transitional Cell - mortality</subject><subject>Carcinoma, Transitional Cell - secondary</subject><subject>Chemotherapy</subject><subject>Drug Resistance, Neoplasm</subject><subject>Female</subject><subject>Hemoglobin</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>L-Lactate dehydrogenase</subject><subject>Leukocytes (neutrophilic)</subject><subject>Lymphocytes</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Multivariate analysis</subject><subject>Neutrophils</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Pembrolizumab</subject><subject>Platinum</subject><subject>Prognosis</subject><subject>Progression-Free Survival</subject><subject>Retrospective Studies</subject><subject>Surgical Oncology</subject><subject>Targeted cancer therapy</subject><subject>Urinary Bladder Neoplasms - drug therapy</subject><subject>Urinary Bladder Neoplasms - mortality</subject><subject>Urinary Bladder Neoplasms - pathology</subject><subject>Urologic Neoplasms - drug therapy</subject><subject>Urologic Neoplasms - immunology</subject><subject>Urologic Neoplasms - mortality</subject><subject>Urologic Neoplasms - pathology</subject><subject>Urological cancer</subject><subject>Urothelial carcinoma</subject><issn>1341-9625</issn><issn>1437-7772</issn><issn>1437-7772</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctu1TAQhiNERS_wAiyQJTZsQu04iRN2VdXLkYqQgC5YRRNn3Lok9sEXqtPn4UGZcg4gsWBh2Za_-cfz_0XxUvC3gnN1HAUXtSp5VdNqWlmqJ8WBqKUqlVLVUzrLWpR9WzX7xWGMd5wL1TbVs2Jfdp2UQsiD4sdFjgm-I_voc4wbtlqW7JBF7QMyiAzYOvgb52Oymo3WLxC-YmDWsTUkiy5Fdm_TLVvPdHV5KQOaADr5sGELJiDxx8ocfLrF2cLMNARtHQmxFBASTjsBXMbgZ_uQFxjfsS_Xny5X709YTHnaPC_2DMwRX-z2o-L6_Ozz6WV59eFidXpyVWoaP5UChDGqr_TUTxzH0SihxITcdNBA23dd34GuWqOg4dwA19r0spISeN-Msp_kUfFmq0szf8sY07DYqHGewSHZM0je1k0nmlYQ-vof9M7n4Oh3RPWqIkw0RFVbSgcfI1kzrIMlCzeD4MNjhsM2w4EyHH5lOCgqerWTzuOC05-S36ERILdApCd3g-Fv7__I_gQSGqs4</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Tanabe, Kenji</creator><creator>Kobayashi, Shuichiro</creator><creator>Maezawa, Yuya</creator><creator>Ishihara, Kensaku</creator><creator>Inoue, Naoki</creator><creator>Izumi, Keita</creator><creator>Fujiwara, Motohiro</creator><creator>Toide, Masahiro</creator><creator>Yamamoto, Takanobu</creator><creator>Uehara, Sho</creator><creator>Araki, Saori</creator><creator>Inoue, Masaharu</creator><creator>Takazawa, Ryoji</creator><creator>Numao, Noboru</creator><creator>Ohtsuka, Yukihiro</creator><creator>Tanaka, Hajime</creator><creator>Yoshida, Soichiro</creator><creator>Fujii, Yasuhisa</creator><general>Springer Nature Singapore</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0000-7290-1826</orcidid></search><sort><creationdate>20240901</creationdate><title>Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study</title><author>Tanabe, Kenji ; Kobayashi, Shuichiro ; Maezawa, Yuya ; Ishihara, Kensaku ; Inoue, Naoki ; Izumi, Keita ; Fujiwara, Motohiro ; Toide, Masahiro ; Yamamoto, Takanobu ; Uehara, Sho ; Araki, Saori ; Inoue, Masaharu ; Takazawa, Ryoji ; Numao, Noboru ; Ohtsuka, Yukihiro ; Tanaka, Hajime ; Yoshida, Soichiro ; Fujii, Yasuhisa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c256t-1a1ff792cd9d0ebbf7171de0f8a5a698898ac26f7a500fa0ccf93233a095b39d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antineoplastic Agents, Immunological - therapeutic use</topic><topic>Biomarkers, Tumor</topic><topic>C-reactive protein</topic><topic>Cancer Research</topic><topic>Carcinoma, Transitional Cell - drug therapy</topic><topic>Carcinoma, Transitional Cell - mortality</topic><topic>Carcinoma, Transitional Cell - secondary</topic><topic>Chemotherapy</topic><topic>Drug Resistance, Neoplasm</topic><topic>Female</topic><topic>Hemoglobin</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>L-Lactate dehydrogenase</topic><topic>Leukocytes (neutrophilic)</topic><topic>Lymphocytes</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Multivariate analysis</topic><topic>Neutrophils</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Pembrolizumab</topic><topic>Platinum</topic><topic>Prognosis</topic><topic>Progression-Free Survival</topic><topic>Retrospective Studies</topic><topic>Surgical Oncology</topic><topic>Targeted cancer therapy</topic><topic>Urinary Bladder Neoplasms - drug therapy</topic><topic>Urinary Bladder Neoplasms - mortality</topic><topic>Urinary Bladder Neoplasms - pathology</topic><topic>Urologic Neoplasms - drug therapy</topic><topic>Urologic Neoplasms - immunology</topic><topic>Urologic Neoplasms - mortality</topic><topic>Urologic Neoplasms - pathology</topic><topic>Urological cancer</topic><topic>Urothelial carcinoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tanabe, Kenji</creatorcontrib><creatorcontrib>Kobayashi, Shuichiro</creatorcontrib><creatorcontrib>Maezawa, Yuya</creatorcontrib><creatorcontrib>Ishihara, Kensaku</creatorcontrib><creatorcontrib>Inoue, Naoki</creatorcontrib><creatorcontrib>Izumi, Keita</creatorcontrib><creatorcontrib>Fujiwara, Motohiro</creatorcontrib><creatorcontrib>Toide, Masahiro</creatorcontrib><creatorcontrib>Yamamoto, Takanobu</creatorcontrib><creatorcontrib>Uehara, Sho</creatorcontrib><creatorcontrib>Araki, Saori</creatorcontrib><creatorcontrib>Inoue, Masaharu</creatorcontrib><creatorcontrib>Takazawa, Ryoji</creatorcontrib><creatorcontrib>Numao, Noboru</creatorcontrib><creatorcontrib>Ohtsuka, Yukihiro</creatorcontrib><creatorcontrib>Tanaka, Hajime</creatorcontrib><creatorcontrib>Yoshida, Soichiro</creatorcontrib><creatorcontrib>Fujii, Yasuhisa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tanabe, Kenji</au><au>Kobayashi, Shuichiro</au><au>Maezawa, Yuya</au><au>Ishihara, Kensaku</au><au>Inoue, Naoki</au><au>Izumi, Keita</au><au>Fujiwara, Motohiro</au><au>Toide, Masahiro</au><au>Yamamoto, Takanobu</au><au>Uehara, Sho</au><au>Araki, Saori</au><au>Inoue, Masaharu</au><au>Takazawa, Ryoji</au><au>Numao, Noboru</au><au>Ohtsuka, Yukihiro</au><au>Tanaka, Hajime</au><au>Yoshida, Soichiro</au><au>Fujii, Yasuhisa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study</atitle><jtitle>International journal of clinical oncology</jtitle><stitle>Int J Clin Oncol</stitle><addtitle>Int J Clin Oncol</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>29</volume><issue>9</issue><spage>1302</spage><epage>1310</epage><pages>1302-1310</pages><issn>1341-9625</issn><issn>1437-7772</issn><eissn>1437-7772</eissn><abstract>Background
This study aimed to investigate the prognostic value of the Gustave Roussy Immune score (GRIm-score) in platinum-refractory metastatic urothelial carcinoma (UC) treated with pembrolizumab.
Methods
This multicenter retrospective study (YUSHIMA study) evaluated 331 patients with metastatic UC treated with pembrolizumab after platinum-based chemotherapy between January 2018 and June 2023 at 13 institutions. We collected pretreatment variables, including the GRIm-score based on serum albumin, lactate dehydrogenase, and neutrophil-to-lymphocyte ratio. The patients were divided into low and high GRIm-score groups. Prognostic factors for overall survival (OS) and progression-free survival (PFS) were determined using the multivariate Cox proportional hazard model.
Results
During the median follow-up period of 7.3 months, 278 (84%) patients showed disease progression, and 223 (67%) died from any cause. Multivariate analysis revealed that the high GRIm-score group was an independent and significant adverse prognostic factor of both OS and PFS (hazard ratio, 1.65 and 1.82, respectively; both
p
< 0.001) along with Eastern Cooperative Oncology Group Performance Status of ≥ 2 (both
p
< 0.001), presence of visceral metastasis (both
p
< 0.001), and hemoglobin of < 9.2 g/dL (
p
= 0.030 and
p
= 0.038). C-reactive protein of > 42 mg/L was a significant prognostic factor for OS (
p
= 0.001).
Conclusion
The GRIm-score is an independent prognostic marker for survival outcomes in patients with platinum-refractory metastatic UC treated with pembrolizumab.</abstract><cop>Singapore</cop><pub>Springer Nature Singapore</pub><pmid>38833113</pmid><doi>10.1007/s10147-024-02563-7</doi><tpages>9</tpages><orcidid>https://orcid.org/0009-0000-7290-1826</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-9625 |
| ispartof | International journal of clinical oncology, 2024-09, Vol.29 (9), p.1302-1310 |
| issn | 1341-9625 1437-7772 1437-7772 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3064581561 |
| source | MEDLINE; SpringerLink (Online service) |
| subjects | Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological - therapeutic use Biomarkers, Tumor C-reactive protein Cancer Research Carcinoma, Transitional Cell - drug therapy Carcinoma, Transitional Cell - mortality Carcinoma, Transitional Cell - secondary Chemotherapy Drug Resistance, Neoplasm Female Hemoglobin Humans Immunotherapy L-Lactate dehydrogenase Leukocytes (neutrophilic) Lymphocytes Male Medical prognosis Medicine Medicine & Public Health Metastases Metastasis Middle Aged Monoclonal antibodies Multivariate analysis Neutrophils Oncology Original Article Pembrolizumab Platinum Prognosis Progression-Free Survival Retrospective Studies Surgical Oncology Targeted cancer therapy Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - mortality Urinary Bladder Neoplasms - pathology Urologic Neoplasms - drug therapy Urologic Neoplasms - immunology Urologic Neoplasms - mortality Urologic Neoplasms - pathology Urological cancer Urothelial carcinoma |
| title | Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T20%3A47%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gustave%20Roussy%20Immune%20score%20as%20a%20prognostic%20biomarker%20in%20patients%20with%20platinum-refractory%20metastatic%20urothelial%20carcinoma%20treated%20with%20pembrolizumab:%20YUSHIMA%20study&rft.jtitle=International%20journal%20of%20clinical%20oncology&rft.au=Tanabe,%20Kenji&rft.date=2024-09-01&rft.volume=29&rft.issue=9&rft.spage=1302&rft.epage=1310&rft.pages=1302-1310&rft.issn=1341-9625&rft.eissn=1437-7772&rft_id=info:doi/10.1007/s10147-024-02563-7&rft_dat=%3Cproquest_cross%3E3097258115%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3097258115&rft_id=info:pmid/38833113&rfr_iscdi=true |